COMBINED CANCER THERAPY OF B7-H3 AND CD47 IMMUNE CHECKPOINT INHBITIOR AND METHODS OF USE

The present disclosure generally relates to compositions and methods for treating a solid tumor in a subject, wherein administering compositions having a combination of an inhibitor of B7-H3 (CD276) and an inhibitor of CD47-SIRPα can inflame a cold tumor microenvironment. La présente divulgation con...

Full description

Saved in:
Bibliographic Details
Main Authors PARSONS, E. Ramon, CELEBI, Julide Tok, TIPHAINE, C. Martin, HSU, Min
Format Patent
LanguageEnglish
French
Published 27.05.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure generally relates to compositions and methods for treating a solid tumor in a subject, wherein administering compositions having a combination of an inhibitor of B7-H3 (CD276) and an inhibitor of CD47-SIRPα can inflame a cold tumor microenvironment. La présente divulgation concerne de manière générale des compositions et des méthodes de traitement d'une tumeur solide chez un sujet. L'administration de compositions comprenant une combinaison d'un inhibiteur du B7-H3 (CD276) et un inhibiteur du CD47-SIRPα peut provoquer l'inflammation d'un microenvironnement de tumeur froide.
Bibliography:Application Number: WO2021US60025